

Contents

Part I General Aspects

- 1 Why Green and Sustainable Pharmacy? 3**
Klaus Kümmerer
- 2 Pharmaceuticals in the Environment: Moving from a Problem to a Solution 11**
John P. Sumpter
- 3 Pharmaceuticals in Society 23**
David J. Triggle
- 4 Green(er) Pharmacy 37**
James H. Clark, Simon W. Breeden, and Louise Summerton
- 5 Creating a Sustainability Culture – A (Human Resources) Management Perspective for Sustainable Pharmacy 61**
Michael Läufer
- 6 Reducing the Ecological Footprint of Pharmaceutical Usage: Linkages Between Healthcare Practices and the Environment 77**
Christian G. Daughton and Ilene S. Ruhoy

Part II Development, Synthesis and Production and Distribution of Pharmaceuticals

- 7 Ecopharmacostewardship – A Pharmaceutical Industry Perspective 105**
David Taylor
- 8 Protein and Peptide Therapeutics: An Example of “Benign by Nature” Active Pharmaceutical Ingredients 127**
Jürg Oliver Straub
- 9 Rational Design of Molecules by Life Cycle Engineering 135**
Klaus Kümmerer

Part III Use and Disposal of Pharmaceuticals

- 10 Options for a More Environmentally Friendly Handling of Pharmaceuticals** 149
Konrad Götz and Jutta Deffner
- 11 Disposal of Pharmaceutical Waste in Households – A European Survey** 165
Gerald Vollmer
- 12 Pharmaceutical Waste: The Patient Role** 179
Staffan Castensson and Anders Ekedahl
- 13 Forecast of Pharmaceutical Consumption in the Netherlands Using Demographic Projections** 201
Monique van der Aa and Geertjan Kommer

Part IV Emission Management

- 14 Point Sources of Human Pharmaceuticals into the Aquatic Environment** 211
Kevin V. Thomas and Katherine H. Langford
- 15 Pharmaceuticals for Human Use: An Integrated Strategy for Reducing the Contamination of Water Bodies** 225
Florian Keil
- 16 Experiences with the Swedish Environmental Classification Scheme** 243
Åke Wennmalm and Bo Gunnarsson

Part V Incentives, Regulation and the Market

- 17 European Regulations** 253
Eleftheria Kampa, Thomas Dworak, Cornelius Laaser, and Rodrigo Vidaurre
- 18 Regulation and the Market-Incentives** 279
Benoît Roig and Evelyne Touraud
- 19 Do Pharmaceuticals in the Environment Present an Investment Risk?** 287
Andreas Holzer

Part VI Outlook

- 20 Sustainable Health Products and Service Solutions in the Year 2050** 295
Ludwig Metz and Klaus Kümmerer

Contents	xiii
21 Summary and Outlook	299
Klaus Kümmerer Maximilian Hempel, Hans-Christian Schaefer, and Florian Keil	
Index	305